Neil Mendhiratta
Papers
2
Total Citations
40
H-Index
2
About
Neil Mendhiratta is a urologic oncologist whose research focuses on refining the diagnosis and risk stratification of prostate cancer, particularly through advanced imaging and targeted biopsy techniques. His most cited work investigates the prognostic value of the PI-RADS version 2 scoring system on 3 Tesla multiparametric MRI. In a landmark 2018 study (27 citations), he demonstrated that PI-RADS v2 scores not only indicate the likelihood of cancer but also predict oncologic outcomes in men with Gleason 3+4 disease, helping to guide treatment decisions beyond initial biopsy. Mendhiratta has also contributed a comprehensive review of biopsy approaches beyond traditional transrectal ultrasound-guided methods (13 citations), cataloging emerging techniques such as MRI-targeted, transperineal, and fusion biopsies. His work bridges radiology and urology, emphasizing how imaging biomarkers can personalize prostate cancer management. By showing that MRI findings correlate with long-term prognosis, Mendhiratta has helped advance a more nuanced, risk-adapted approach to prostate cancer care, reducing unnecessary interventions while improving detection of clinically significant disease.
Research Focus
Key Achievements
Top Papers
- 1
- 2